Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Work will shortly be underway on the new IMS-Tetsuya Nakamura Building, home to the new Institute of Developmental and Regenerative Medicine at Old Road Campus. The formal ground-breaking ceremony, which took place towards the end of last year, was organised by the Medical Sciences Development team in collaboration with the Department of Paediatrics.

IDRM ground-breaking – work gets underway! © Rob Judges
Image (from left to right) 1. Professor Georg Holländer 2. Dr Tetsuya Nakamura (Itabashi Medical System Group CEO) 3. British Heart Foundation’s CEO, Mr Simon Gillespie 4. The Chancellor, the Right Honourable Lord Patten of Barnes 5. Professor Paul Riley

This £35m centre, which is set to open in the summer of 2021, will bring together 220 leading researchers from Oxford and across the globe. Their collaboration will enable them to understand the cellular and molecular control of normal human development and to harness this knowledge for the design of novel therapies that correct birth defects and repair adult organs.

Two thirds of all deaths worldwide are due to non-communicable diseases; many of these are cardiovascular, neurological or immune system disorders. Scientists in the new IDRM building will study the cellular and molecular mechanisms underpinning normal development and what goes wrong in those with birth defects.

Regenerative medicine has the potential to offer treatments for diseases and disorders by providing the body with the means to repair, replace, restore and regenerate damaged or diseased cells, tissues and organs. Advances will be translated into patient treatment and care through drug discovery and bioengineering to deliver treatments for public benefit.

Under the leadership of Professor Georg Holländer (Hoffmann and Action Medical Research Professor of Paediatrics), Professor Paul Riley (British Heart Foundation Professor of Regenerative Medicine), and Professor Matthew Wood (Professor of Neuroscience), the IDRM will integrate programmes in cardiovascular, neurological and immunological science that are dedicated to deciphering the cellular and molecular mechanisms underpinning the developmental biology essential for human health.

This vision has been made possible through a partnership between the University of Oxford, the British Heart Foundation and the philanthropist Dr Tetsuya Nakamura (Itabashi Medical System Group CEO) and his foundation.

Dr Nakamura and his wife, Mrs Naoko Nakamura, the British Heart Foundation’s CEO, Simon Gillespie, and other generous donors to this project were invited to attend the official ground-breaking ceremony. We were honoured to be joined by the Chancellor, the Right Honourable Lord Patten of Barnes, who presided over the ceremony.

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team in Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

Oxford spinout trials revolutionary bioelectronic implant to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.

COVID-19 is a leading cause of death in children and young people in the US

A new study led by researchers at the University of Oxford’s Department of Computer Science has found that, between 2021 and 2022, COVID-19 was a leading cause of death in children and young people in the United States, ranking eighth overall. The results demonstrate that pharmaceutical and public health interventions should continue to be applied to limit the spread of the coronavirus and protect again severe disease in this age group.

Three or more concussions linked with worse brain function in later life

Experiencing three or more concussions is linked with worsened brain function in later life, according to new research.

New blood test could save lives of heart attack victims

Researchers in the Department of Physiology, Anatomy and Genetics (DPAG) have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.